Amgen (AMGN) is a Top-Ranked Growth Stock: Should You Buy?

Company Overview - Amgen is one of the largest biotech companies globally, with a strong presence in oncology/hematology, cardiovascular disease, inflammation, bone health, and rare diseases markets [11] - The company has developed successful drugs such as Epogen and Neupogen, and launched next-generation products like Aranesp and Neulasta [11] - Amgen's acquisition of Immunex Corporation provided access to the blockbuster drug Enbrel, although older drugs are facing declining sales due to competition [11] Financial Performance - Amgen has a Zacks Rank of 3 (Hold) and a VGM Score of A, indicating a solid position in the market [12] - The company is forecasted to achieve year-over-year earnings growth of 5.1% for the current fiscal year [12] - Recent upward revisions in earnings estimates by five analysts for fiscal 2025 have increased the Zacks Consensus Estimate by $0.09 to $20.85 per share [12] - Amgen has an average earnings surprise of +8.3%, reflecting its ability to exceed earnings expectations [12] Investment Potential - With a solid Zacks Rank and top-tier Growth and VGM Style Scores, Amgen is recommended for investors looking for growth opportunities [13]